Lexicon Pharma (LXRX) Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. DFTX
4. IBM
5. META
6. MU
7. DPZ
8. ACN
9. ZENA
10. CNC

Go back to Lexicon Pharma (LXRX) Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

July 30, 2020 7:15 AM EDT

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain

Sale of XERMELO to TerSera to Yield Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer

Substantial Debt Reduction, Including Full Repayment of Secured Loan

THE WOODLANDS, Texas, July 30, 2020 (GLOBE NEWSWIRE) --... More

Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO

July 30, 2020 7:10 AM EDT

THE WOODLANDS, Texas and DEERFIELD, Ill., July 30, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicons rights, title and interest in XERMELO® (telotristat ethyl).  

Pursuant to the terms of the agreement, TerSera will pay Lexicon... More